Corporate Profile
Founded in 1992, Conceptus®, Inc. is dedicated to the revolutionary design, development, and marketing of innovative solutions to advance women's health. We developed the market leading Essure® procedure, the first-ever non-surgical permanent birth control method. After a decade on the market, Essure remains the most effective form of permanent birth control* available worldwide. We are committed to making Essure the standard of care for permanent birth control, and we intend to provide additional women's health solutions for both patients and physicians.
*based on four years of clinical study data
Shareholder information
Exchange:
Conceptus, Inc.'s common stock trades on The NASDAQ Global Select MarketSM under the symbol CPTS.
Transfer agent:
BNY Mellon Shareowner Services
P.O. Box 358015
Pittsburgh, PA 15252-8015
(877) 258-2911 (phone)
www.bnymellon.com/shareowner/equityaccess
View all » 
Recent Releases
Feb 7, 2012
Conceptus(R) Intends to Appeal Court Order in Hologic Patent Infringement Case
Jan 31, 2012
Conceptus(R) to Hold Fourth Quarter Financial Results Conference Call on February 23, 2012
View all »Events & Presentations
Feb 23, 2012
Conceptus 2011 Fourth Quarter Financial Results
Listen to webcast